159191-56-7 Usage
Description
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is an organic compound characterized by its unique structure that features a tert-butyldimethylsilyloxy group attached to a phenylboronate moiety. 4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is known for its reactivity and versatility in various chemical reactions and synthetic applications.
Uses
Used in Chemical Synthesis:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a reactant in asymmetric addition reactions with β-substituted cyclic enones, hydroarylation and heterocyclization with phenylpropiolates, and double Suzuki-Miyaura coupling reactions. It serves as a key intermediate in the synthesis of complex organic molecules due to its ability to participate in various types of chemical transformations.
Used in Material Science:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a starting material for the synthesis of red electroluminescent polyfluorenes. These materials have potential applications in the development of organic light-emitting diodes (OLEDs) and other optoelectronic devices.
Used in Pharmaceutical Chemistry:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a reactant in the synthesis of biologically active molecules, including phenylpyridone derivatives as MCH1R antagonists, atromentin and its O-alkylated derivatives, and gelatinases and MT1-MMP inhibitors. These molecules have potential therapeutic applications in various medical conditions, such as cancer, neurological disorders, and inflammatory diseases.
Used in the Pharmaceutical Industry:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a synthetic building block for the development of novel drug candidates, particularly in the areas of oncology, neurology, and inflammation. Its unique reactivity and structural features make it a valuable asset in the design and synthesis of new therapeutic agents.
Used in the Material Science Industry:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a precursor in the development of advanced materials for optoelectronics, such as red electroluminescent polyfluorenes. These materials have potential applications in the creation of more efficient and environmentally friendly OLEDs and other light-emitting technologies.
Check Digit Verification of cas no
The CAS Registry Mumber 159191-56-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,9,1,9 and 1 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 159191-56:
(8*1)+(7*5)+(6*9)+(5*1)+(4*9)+(3*1)+(2*5)+(1*6)=157
157 % 10 = 7
So 159191-56-7 is a valid CAS Registry Number.
InChI:InChI=1/C12H21BO3Si/c1-12(2,3)17(4,5)16-11-8-6-10(7-9-11)13(14)15/h6-9,14-15H,1-5H3
159191-56-7Relevant articles and documents
Flexible Analogues of Azaindole DYRK1A Inhibitors Elicit Cytotoxicity in Glioblastoma Cells
Zhou, Qingqing,Reekie, Tristan A.,Abbassi, Ramzi H.,Venkata, Dinesh Indurthi,Font, Josep S.,Ryan, Renae M.,Rendina, Louis M.,Munoz, Lenka,Kassiou, Michael
, p. 789 - 797 (2018)
DYRK1A is a novel target for epidermal growth factor receptor (EGFR)-dependent glioblastoma and it represents a promising strategy for cancer therapy. DYRK1A inhibition has been found to promote EGFR degradation in glioblastoma cells by triggering endocyt
Polymerizable compounds. Liquid crystal composition and liquid crystal display device
-
, (2021/09/08)
A polymerizable compound having a formula of formula (I): Ring A, ring B, Z1 , Z2 , R, P, n And m are as described in the specification and the application patent range, respectively. The liquid crystal composition containing the pol
Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A
Zhou, Qingqing,Reekie, Tristan A.,Abbassi, Ramzi H.,Indurthi Venkata, Dinesh,Font, Josep S.,Ryan, Renae M.,Munoz, Lenka,Kassiou, Michael
, p. 5852 - 5869 (2018/11/10)
Dual-specificity tyrosine phosphorylation-related kinase 1A (DYRK1A) is a dual-specificity protein kinase that catalyses phosphorylation and autophosphorylation. Higher DYRK1A expression correlates with cancer, in particular glioblastoma present within the brain. We report here the synthesis and biological evaluation of new heterocyclic diphenolic derivatives designed as novel DYRK1A inhibitors. The generation of these heterocycles such as benzimidazole, imidazole, naphthyridine, pyrazole-pyridines, bipyridine, and triazolopyrazines was made based on the structural modification of the lead DANDY and tested for their ability to inhibit DYRK1A. None of these derivatives showed significant DYRK1A inhibition but provide valuable knowledge around the importance of the 7-azaindole moiety. These data will be of use for developing further structure-activity relationship studies to improve the selective inhibition of DYRK1A.
